Survival increases among patients with amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
FDA Highlights – by Bruce Sylvester – Patients with selected immunoglobulin light chain amyloidosis who are treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) have a… read more.